Valerio Therapeutics Société anonyme (ALVIO.PA)
EUR 0.08
(3.31%)
EUR 0.08
(3.31%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.8 Million EUR | 24.74% |
| 2022 | 1.44 Million EUR | -64.48% |
| 2021 | 4.06 Million EUR | 128.72% |
| 2020 | 1.77 Million EUR | -58.58% |
| 2019 | 4.28 Million EUR | -30.01% |
| 2018 | 6.12 Million EUR | -35.54% |
| 2017 | 9.5 Million EUR | 114.85% |
| 2016 | 4.42 Million EUR | 27.05% |
| 2015 | 3.48 Million EUR | -84.23% |
| 2014 | 22.08 Million EUR | 1405.44% |
| 2013 | 1.46 Million EUR | -63.59% |
| 2012 | 4.02 Million EUR | 24.67% |
| 2011 | 3.23 Million EUR | -85.66% |
| 2010 | 22.53 Million EUR | 198.98% |
| 2009 | 7.53 Million EUR | -7.8% |
| 2008 | 8.17 Million EUR | 131.6% |
| 2007 | 3.52 Million EUR | 667.52% |
| 2006 | 459.83 Thousand EUR | 0.0% |
| 2005 | - EUR | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 44.5 Thousand EUR | -95.06% |
| 2024 Q2 | 44.5 Thousand EUR | 0.0% |
| 2023 Q2 | - EUR | 0.0% |
| 2023 Q3 | 900 Thousand EUR | 0.0% |
| 2023 Q4 | 900 Thousand EUR | 0.0% |
| 2023 FY | 1.8 Million EUR | 24.74% |
| 2023 Q1 | - EUR | -100.0% |
| 2022 FY | 1.44 Million EUR | -64.48% |
| 2022 Q2 | - EUR | 0.0% |
| 2022 Q3 | 721.5 Thousand EUR | 0.0% |
| 2022 Q4 | 1.44 Million EUR | 100.0% |
| 2022 Q1 | - EUR | -100.0% |
| 2021 Q2 | 589 Thousand EUR | 100.0% |
| 2021 Q4 | 3.47 Million EUR | 100.0% |
| 2021 FY | 4.06 Million EUR | 128.72% |
| 2021 Q1 | 294.5 Thousand EUR | -57.56% |
| 2021 Q3 | 1.73 Million EUR | 194.82% |
| 2020 FY | 1.77 Million EUR | -58.58% |
| 2020 Q3 | 347 Thousand EUR | -67.93% |
| 2020 Q4 | 694 Thousand EUR | 100.0% |
| 2020 Q2 | 1.08 Million EUR | 100.0% |
| 2020 Q1 | 541 Thousand EUR | -79.08% |
| 2019 Q3 | 1.29 Million EUR | -24.08% |
| 2019 Q4 | 2.58 Million EUR | 100.0% |
| 2019 Q2 | 1.7 Million EUR | 100.0% |
| 2019 FY | 4.28 Million EUR | -30.01% |
| 2019 Q1 | 851.5 Thousand EUR | -57.69% |
| 2018 Q1 | 1.05 Million EUR | -65.75% |
| 2018 FY | 6.12 Million EUR | -35.54% |
| 2018 Q4 | 2.01 Million EUR | 0.0% |
| 2018 Q3 | 2.01 Million EUR | 91.48% |
| 2018 Q2 | 1.05 Million EUR | 0.0% |
| 2017 Q4 | 3.06 Million EUR | 0.0% |
| 2017 FY | 9.5 Million EUR | 114.85% |
| 2017 Q1 | 1.68 Million EUR | 32.3% |
| 2017 Q2 | 1.68 Million EUR | 0.0% |
| 2017 Q3 | 3.06 Million EUR | 82.3% |
| 2016 Q3 | 1.27 Million EUR | 35.52% |
| 2016 FY | 4.42 Million EUR | 27.05% |
| 2016 Q1 | 939 Thousand EUR | -3.59% |
| 2016 Q2 | 939 Thousand EUR | 0.0% |
| 2016 Q4 | 1.27 Million EUR | 0.0% |
| 2015 Q1 | 766.5 Thousand EUR | -92.85% |
| 2015 Q2 | 766.5 Thousand EUR | 0.0% |
| 2015 FY | 3.48 Million EUR | -84.23% |
| 2015 Q4 | 974 Thousand EUR | 0.0% |
| 2015 Q3 | 974 Thousand EUR | 27.07% |
| 2014 Q1 | 326.41 Thousand EUR | 4.98% |
| 2014 FY | 22.08 Million EUR | 1405.44% |
| 2014 Q3 | 10.71 Million EUR | 3182.33% |
| 2014 Q2 | 326.41 Thousand EUR | 0.0% |
| 2014 Q4 | 10.71 Million EUR | 0.0% |
| 2013 FY | 1.46 Million EUR | -63.59% |
| 2013 Q2 | 422.44 Thousand EUR | 0.0% |
| 2013 Q1 | 422.44 Thousand EUR | 0.0% |
| 2013 Q3 | 310.91 Thousand EUR | -26.4% |
| 2013 Q4 | 310.91 Thousand EUR | 0.0% |
| 2012 FY | 4.02 Million EUR | 24.67% |
| 2011 FY | 3.23 Million EUR | -85.66% |
| 2010 FY | 22.53 Million EUR | 198.98% |
| 2009 FY | 7.53 Million EUR | -7.8% |
| 2008 FY | 8.17 Million EUR | 131.6% |
| 2007 FY | 3.52 Million EUR | 667.52% |
| 2006 FY | 459.83 Thousand EUR | 0.0% |
| 2005 FY | - EUR | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ABIONYX Pharma SA | 4.64 Million EUR | 61.207% |
| ABIVAX Société Anonyme | 4.62 Million EUR | 61.047% |
| Adocia SA | 2.15 Million EUR | 16.279% |
| Aelis Farma SA | 9.05 Million EUR | 80.119% |
| Biophytis S.A. | - EUR | -Infinity% |
| Advicenne S.A. | 3.15 Million EUR | 42.875% |
| genOway Société anonyme | 20.04 Million EUR | 91.021% |
| IntegraGen SA | 12.53 Million EUR | 85.643% |
| Medesis Pharma S.A. | 300.03 Thousand EUR | -499.932% |
| Neovacs S.A. | 533.41 Thousand EUR | -237.45% |
| NFL Biosciences SA | - EUR | -Infinity% |
| Plant Advanced Technologies SA | 1.68 Million EUR | -7.046% |
| Quantum Genomics Société Anonyme | 19.79 Thousand EUR | -8992.746% |
| Sensorion SA | 4.74 Million EUR | 62.05% |
| Theranexus Société Anonyme | 296.33 Thousand EUR | -507.429% |
| TME Pharma N.V. | 17 Thousand EUR | -10488.235% |
| Valbiotis SA | 4.73 Million EUR | 61.969% |
| TheraVet SA | 1.07 Million EUR | -66.967% |
| argenx SE | 1.13 Billion EUR | 99.841% |
| BioSenic S.A. | 543 Thousand EUR | -231.492% |
| Celyad Oncology SA | 102 Thousand EUR | -1664.706% |
| DBV Technologies S.A. | - EUR | -Infinity% |
| Galapagos NV | 239.72 Million EUR | 99.249% |
| Genfit S.A. | 28.56 Million EUR | 93.699% |
| GeNeuro SA | - EUR | -Infinity% |
| Hyloris Pharmaceuticals SA | 2.08 Million EUR | 13.752% |
| Innate Pharma S.A. | 51.9 Million EUR | 96.532% |
| Inventiva S.A. | 17.47 Million EUR | 89.701% |
| MaaT Pharma SA | 2.22 Million EUR | 19.21% |
| MedinCell S.A. | 9.16 Million EUR | 80.349% |
| Nanobiotix S.A. | 30.05 Million EUR | 94.012% |
| Onward Medical N.V. | 532 Thousand EUR | -238.346% |
| Oryzon Genomics S.A. | 14.19 Million EUR | 87.316% |
| OSE Immunotherapeutics SA | 2.22 Million EUR | 19.174% |
| Oxurion NV | 263 Thousand EUR | -584.411% |
| Pharming Group N.V. | 245.31 Million EUR | 99.266% |
| Poxel S.A. | 1.98 Million EUR | 9.137% |
| GenSight Biologics S.A. | 1.26 Million EUR | -42.068% |
| Transgene SA | 1.18 Million EUR | -52.027% |
| Financière de Tubize SA | - EUR | -Infinity% |
| UCB SA | 5.25 Billion EUR | 99.966% |
| Valneva SE | 153.71 Million EUR | 98.829% |
| Vivoryon Therapeutics N.V. | -3.62 Million EUR | 149.724% |